A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects

Clinical trial NCT02797847 · COMPLETED

Trial details

NCT number: NCT02797847
Sponsor: Alnylam Pharmaceuticals
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)

Start date: 2016-06-07
Primary completion: 2018-01-12
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.